Cotellic
Chemical Name | cobimetinib |
Dosage Form | Tablet (oral; 20 mg) |
Drug Class | Kinase inhibitors |
System | Skin |
Company | Genentech Inc. |
Approval Year | 2015 |
Indication
- To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)